Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest Quizartinib Stories

2014-04-09 09:57:59

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. Results of the research by Johns Hopkins Kimmel Cancer Center investigators, described March 6 in the journal Blood, show that two doses a day of TTT-3002 eliminated leukemia cells in a group of mice within 10 days. The treatment performed as well...

2014-03-06 08:30:02

SAN DIEGO, March 6, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report fourth quarter and full-year 2013 operational results after closing of the NASDAQ Global Market on Thursday, March 20, 2014. A conference call hosted by Michael Martino, president and CEO, and other members of senior management will...

2014-03-04 08:31:11

SAN DIEGO, March 4, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014. Marcy Graham, Ambit's Executive Director of Investor Relations, will provide an overview of the Company...

2014-02-04 08:33:18

SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate,...

2013-12-05 08:29:12

SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Oppenheimer 24(th) Annual Healthcare Conference to be held at the Crown Plaza Hotel in New York City, December 10-11, 2013. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug...

2013-09-19 08:28:11

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013. Michael Martino, Ambit's CEO, will provide an overview of the Company and its...

2013-08-06 16:28:45

SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced that it will report second quarter 2013 operational results after closing of the NASDAQ Global Market on August 13, 2013. Michael Martino, president and chief executive officer, will host a conference call to provide a business update at 5 p.m. EDT (2...

2013-07-03 16:22:44

SAN DIEGO, July 3, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that Michael Martino, president and CEO, is scheduled to present a company overview at the 8(th) Annual JMP Securities Healthcare Conference. Mr. Martino's presentation is scheduled to take place at 9:30 a.m. EDT on Wednesday, July 10, at the St. Regis New York. A live webcast of the presentation will be accessible in the investors section of the company's website, www.ambitbio.com,...

2013-06-28 08:23:47

SAN DIEGO, June 28, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that the company will be added to the Russell MicroCap® Index, effective at close of business on June 28, 2013. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Russell calculates more than 700,000 benchmarks daily covering approximately 98 percent of the investable...

2013-06-26 08:31:25

SAN DIEGO, June 26, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18(th) Congress of the European Hematology Association in Stockholm, Sweden. Data presented included analyses of patients with relapsed or refractory acute myeloid leukemia (AML) from a Phase 2 clinical trial of quizartinib as monotherapy. In the study,...